Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ACE1831 |
Trade Name | |
Synonyms | ACE-1831|ACE 1831 |
Drug Descriptions |
ACE1831 is an antibody conjugated effector cell therapy comprising an anti-CD20 antibody conjugated to gamma delta T-lymphocytes, which potentially leads to tumor cell killing (Cancer Res 2022;82(12_Suppl):Abstract nr 5573). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ACE1831 | ACE1831 | 0 | 0 |
ACE1831 + Cyclophosphamide + Fludarabine | ACE1831 Cyclophosphamide Fludarabine | 0 | 1 |
ACE1831 + Cyclophosphamide + Fludarabine + Obinutuzumab | ACE1831 Cyclophosphamide Fludarabine Obinutuzumab | 0 | 1 |